Multiple Stress Signals Activate Mutant p53 In Vivo
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
p53 levels are tightly regulated in normal cells, and thus, the wild-type p53 protein is nearly undetectable until stimulated through a variety of stresses. In response to stress, p53 is released from its negative regulators, mainly murine double minute 2 (Mdm2), allowing p53 to be stabilized to activate cell-cycle arrest, senescence, and apoptosis programs. Many of the upstream signals that regulate wild-type p53 are known; however, limited information for the regulation of mutant p53 exists. Previously, we showed that wild-type and mutant p53R172H are regulated in a similar manner in the absence of Mdm2 or p16. In addition, this stabilization of mutant p53 is responsible for the gain-of-function metastatic phenotype observed in the mouse. In this report, we examined the role of oncogenes, DNA damage, and reactive oxygen species, signals that stabilize wild-type p53, on the stabilization of mutant p53 in vivo and the consequences of this expression on tumor formation and survival. These factors stabilized mutant p53 protein which oftentimes contributed to exacerbated tumor phenotypes. These findings, coupled with the fact that patients carry p53 mutations without stabilization of p53, suggest that personalized therapeutic schemes may be needed for individual patients depending on their p53 status. Cancer Res; 71(23); 7168–75. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 1×
“Primarily, its stability is regulated by murine double minute 2 (Mdm2), an E3 ubiquitin ligase that targets p53 for proteolytic degradation (3-7).”
BackgroundRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“Primarily, its stability is regulated by murine double minute 2 (Mdm2), an E3 ubiquitin ligase that targets p53 for proteolytic degradation (3-7).”
BackgroundTumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951 · cited 1×
“Primarily, its stability is regulated by murine double minute 2 (Mdm2), an E3 ubiquitin ligase that targets p53 for proteolytic degradation (3-7).”
BackgroundZhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521 · cited 2×
“Mutant Ras or increased levels of c-Myc, for example, stimulate the ARF–Mdm2 complex formation (18, 20-22) which in turn, causes a sequestration of Mdm2 and subsequent stabilization of p53 (23).”
BackgroundMutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308 · cited 1×
“Recently, we and others demonstrated that mutant p53 is inherently unstable in normal tissues and that some of the factors that regulate wild type p53 are also responsible for the stabilization of mutant p53 protein (24-26).”
BackgroundMyc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization
Zindy, F., Eischen, C. M., Randle, D. H., Kamijo, T., Cleveland, J. L., Sherr, C. J., & Roussel, M. F. (1998) · Genes & Development · doi:10.1101/gad.12.15.2424 · Cited by 1,245
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., & Jacks, T. (2001) · Nature · doi:10.1038/35074129 · Cited by 1,179
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132 · cited 1×
“Specifically, mutant p53 enhances proliferation and survival in cells and tumorigenesis inmice when comparedwith cells ormice that are deficient for p53 (1).”
Background
Research works printed but not linked: 25
- Appella, 2001, Post-translational modifications and activation of p53 by genotoxic stresses, Eur J Biochem, 268, 2764, 10.1046/j.1432-1327.2001.02225.x · DOI · Paper page
- Freedman, 1998, Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6, Mol Cell Biol, 18, 7288, 10.1128/MCB.18.12.7288 · DOI · Paper page
- Dornan, 2004, The ubiquitin ligase COP1 is a critical negative regulator of p53, Nature, 429, 86, 10.1038/nature02514 · DOI · Paper page
- Leng, 2003, Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation, Cell, 112, 779, 10.1016/S0092-8674(03)00193-4 · DOI · Paper page
- Chen, 2005, ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor, Cell, 121, 1071, 10.1016/j.cell.2005.03.037 · DOI · Paper page
- Ho, 2005, Activation of p53 by specific agents in potential cancer therapy, Curr Med Chem Anticancer Agents, 5, 131, 10.2174/1568011053174819 · doi:10.2174/1568011053174819
- Soussi, 2005, p53 mutation heterogeneity in cancer, Biochem Biophys Res Commun, 331, 834, 10.1016/j.bbrc.2005.03.190 · DOI · Paper page
- Temkin, 2007, From death receptor to reactive oxygen species and c-Jun N-terminal protein kinase: the receptor-interacting protein 1 odyssey, Immunol Rev, 220, 8, 10.1111/j.1600-065X.2007.00560.x · DOI · Paper page
- Hahn, 2002, Modelling the molecular circuitry of cancer, Nat Rev Cancer, 2, 331, 10.1038/nrc795 · DOI · Paper page
- Sherr, 2001, The INK4a/ARF network in tumour suppression, Nat Rev Mol Cell Biol, 2, 731, 10.1038/35096061 · DOI · Paper page
- de Stanchina, 1998, E1A signaling to p53 involves the p19(ARF) tumor suppressor, Genes Dev, 12, 2434, 10.1101/gad.12.15.2434 · DOI · Paper page
- Stott, 1998, The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2, Embo J, 17, 5001, 10.1093/emboj/17.17.5001 · DOI · Paper page
- Korgaonkar, 2002, ARF function does not require p53 stabilization or Mdm2 relocalization, Mol Cell Biol, 22, 196, 10.1128/MCB.22.1.196-206.2002 · DOI · Paper page
- Terzian, 2008, The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss, Genes Dev, 22, 1337, 10.1101/gad.1662908 · DOI · Paper page
- Adams, 1985, The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice, Nature, 318, 533, 10.1038/318533a0 · DOI · Paper page
- Post, 2010, p53-dependent senescence delays Emu-myc-induced B-cell lymphomagenesis, Oncogene, 29, 1260, 10.1038/onc.2009.423 · DOI · Paper page
- Zheng, 2007, A genetic mouse model for metastatic lung cancer with gender differences in survival, Oncogene, 26, 6896, 10.1038/sj.onc.1210493 · DOI · Paper page
- Evans, 2001, An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2, Oncogene, 20, 4041, 10.1038/sj.onc.1204533 · DOI
- Qiang, 2004, Activation of transcription factor Nrf-2 and its downstream targets in response to moloney murine leukemia virus ts1-induced thiol depletion and oxidative stress in astrocytes, J Virol, 78, 11926, 10.1128/JVI.78.21.11926-11938.2004 · DOI · Paper page
- Martindale, 2002, Cellular response to oxidative stress: signaling for suicide and survival, J Cell Physiol, 192, 1, 10.1002/jcp.10119 · DOI · Paper page
- Kemp, 1994, p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis, Nat Genet, 8, 66, 10.1038/ng0994-66 · DOI · Paper page
- Kastan, 1991, Participation of p53 protein in the cellular response to DNA damage, Cancer Res, 51, 6304
- Li, 2007, Nox2 regulates endothelial cell cycle arrest and apoptosis via p21cip1 and p53, Free Radic Biol Med, 43, 976, 10.1016/j.freeradbiomed.2007.06.001 · DOI · Paper page
- Shackelford, 2000, Oxidative stress and cell cycle checkpoint function, Free Radic Biol Med, 28, 1387, 10.1016/S0891-5849(00)00224-0 · DOI · Paper page
- Sablina, 2005, The antioxidant function of the p53 tumor suppressor, Nat Med, 11, 1306, 10.1038/nm1320 · DOI · Paper page
Cited by
Muller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
Mutant p53: one name, many proteins
Freed-Pastor, W. A., & Prives, C. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,247
Mutant p53 as a guardian of the cancer cell
Mantovani, F., Collavin, L., & Del Sal, G. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0246-9 · Cited by 775
p53 signaling in cancer progression and therapy
Marei, H. E., Althani, A., Afifi, N., Hasan, A., Caceci, T., Pozzoli, G., Morrione, A., Giordano, A., & Cenciarelli, C. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02396-8 · Cited by 588
Metadata
- Authors
- Suh, Y.-A., Post, S. M., Elizondo-Fraire, A. C., Maccio, D. R., Jackson, J. G., El-Naggar, A. K., Van Pelt, C., Terzian, T., & Lozano, G.
- Venue
- Cancer Research
- Published
- 2011-11-29
- Volume
- 71
- Issue
- 23
- Pages
- 7168-7175
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2164263193
- Cited by
- 119
- References
- 16
- FWCI
- 4.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multiple Stress Signals Activate Mutant p53 In Vivo. https://app.cochat.ai/papers/10.1158/0008-5472.can-11-0459
- The paper
- Suh, Y.-A., Post, S. M., Elizondo-Fraire, A. C., Maccio, D. R., Jackson, J. G., El-Naggar, A. K., Van Pelt, C., Terzian, T., & Lozano, G. (2011). Multiple Stress Signals Activate Mutant p53 In Vivo. Cancer Research. https://doi.org/10.1158/0008-5472.can-11-0459
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.